2-(3-甲氧基苯基)乙肼 | 34624-38-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(3-甲氧基苯基)乙肼
• 英文名称: 2-(3-methoxyphenyl)acetohydrazide
• 英文别名: 2-(3-methoxyphenyl)acetic hydrazide
• CAS: 34624-38-9
• 化学式: C₉H₁₂N₂O₂
• mdl: MFCD00085106
• 分子量: 180.206
• InChiKey: XEALVGVRTCEVES-UHFFFAOYSA-N

物化性质

• 熔点：
  89 °C
• 沸点：
  402.6±28.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22
• 海关编码：
  2928000090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

SDS

Name:	2-(3-Methoxyphenyl)ethanohydrazide 97% Material Safety Data Sheet
Synonym:	3-Methoxyphenylacetic acid hydrazid
CAS:	34624-38-9

Section 1 - Chemical Product MSDS Name:2-(3-Methoxyphenyl)ethanohydrazide 97% Material Safety Data Sheet
Synonym:3-Methoxyphenylacetic acid hydrazid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
34624-38-9	2-(3-Methoxyphenyl)ethanohydrazide	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 34624-38-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 45 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H12N2O2
Molecular Weight: 180

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 34624-38-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(3-Methoxyphenyl)ethanohydrazide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 34624-38-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 34624-38-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 34624-38-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(3-甲氧基苯基)乙肼 在 吡啶 、 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 53.0h， 生成 (3,4-dihydroisoquinolin-2(1H)-yl)(5-(3-methoxybenzyl)-1,3,4-oxadiazol-2-yl)methanone
  参考文献：
  名称：

  基于 5-benzyl-1,3,4-thiadiazole-2-carboxamide 的 SIRT2 选择性抑制剂的命中评估结果具有更高的亲和力和选择性

  摘要：

  Sirtuin 2 (SIRT2) 是 sirtuin 家族的成员，属于 III 类组蛋白去乙酰化酶 (HDAC)，主要为胞质，偶有核转位。SIRT2 的酶活性依赖于烟酰胺腺嘌呤二核苷酸 (NAD +) 和 SIRT2 调节翻译后修饰，这些修饰负责组蛋白和非组蛋白底物中赖氨酸残基的去乙酰化。因此，SIRT2 很可能影响多种细胞过程，例如信号传导、基因表达、衰老、自噬，并已被确定为与炎症、神经退行性疾病和癌症相关的潜在药物靶点。因此，探索潜在的选择性抑制剂对于准确了解酶功能至关重要。在这里，我们报告了一系列杂芳基-2-羧酰胺杂化物，在中心杂环的 5 位带有取代的苄基或取代的苯氧基。合成的化合物针对 SIRT1-3 和 MCF-7 人乳腺癌细胞系进行筛选，以评估其生物活性。最好的 SIRT2 抑制谱由ST29 (SIRT2 IC 50  = 38.69 μM) 和ST30 (SIRT2 IC 50 =

  DOI：

  10.1016/j.bioorg.2022.105746
• 作为产物：
  描述：

  3-甲氧基苯基乙酰氯 在 一水合肼 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以86%的产率得到2-(3-甲氧基苯基)乙肼
  参考文献：
  名称：

  Synthesis, Crystal Structure, Anti-inflammatory and Anti-hyperglycemic Activities of Novel 3,4-Disubstituted 1,2,4-Triazol-5(4H)-one Derivatives

  摘要：

  合成了一系列3,4-二取代1,2,4-三唑-5(4H)-酮5a-r，具有不同的甲氧基苯基、氟苯基、甲苯基和苯基。该化合物通过将肼类羧酰胺4a-r在2N氢氧化钠溶液中回流脱氢环化而制备而成。肼类羧酰胺4a-r是通过相应芳香烃羧酸肼的缩合反应与氟、甲苯和甲氧基苯异氰酸酯合成的。新合成的化合物（5ar）通过红外光谱、1H NMR和13C NMR进行表征。其中一种化合物5a的结构通过单晶X射线衍射分析确定。所有合成的化合物均被筛选用于抗炎和抗糖尿病（α-葡萄糖苷酶和α-淀粉酶抑制）活性，以识别可能用于预防与糖尿病和炎症相关的损伤的新药物。化合物5j、5k和5m以剂量依赖的方式降低II型胶原蛋白的表达；同样，5l以剂量依赖的方式降低兔关节软骨细胞中的COX-2表达，具有很强的抗炎潜力，而一些衍生物包括5c、5e、5g和5h则引起炎症。同时，与参比标准阿卡波糖相比，化合物5b、5f、5k和5q表现出优秀的α-葡萄糖苷酶和中等α-淀粉酶抑制特性，而化合物5g、5h、5i、5j、5l和5o在这一系列中显示出中等到低的酶抑制潜力。

  DOI：

  10.2174/1573406410666140327142912

文献信息

• An SAR study of hydroxy-trifluoromethylpyrazolines as inhibitors of Orai1-mediated store operated Ca2+ entry in MDA-MB-231 breast cancer cells using a convenient Fluorescence Imaging Plate Reader assay
  作者：Ralph J. Stevenson、Iman Azimi、Jack U. Flanagan、Marco Inserra、Irina Vetter、Gregory R. Monteith、William A. Denny

  DOI：10.1016/j.bmc.2018.05.012

  日期：2018.7

  structures as 5-hydroxy-5-trifluoromethylpyrazolines, a series of analogues was prepared via thermal condensation reactions between substituted acylhydrazones and trifluoromethyl 1,3-dicarbonyl arenes. Structure-activity relationship (SAR) studies showed that small lipophilic substituents at the 2- and 3-positions of the RHS and 2-, 3- and 4-postions of the LHS terminal benzene rings improved activity

  蛋白质Orai1和STIM1控制存储操作的Ca 2+进入（SOCE）进入细胞。SOCE对于MDA-MB-231人三阴性乳腺癌（TNBC）细胞的迁移，侵袭和转移很重要，并且已被提议作为癌症药物发现的靶标。通过荧光成像板读数器（FLIPR）Ca 2+测量，中等通量筛选中的两种命中化合物显示出令人鼓舞的MDA-MB-231细胞中SOCE抑制作用分析。在对这些命中进行NMR光谱分析并将其结构重新分配为5-羟基-5-三氟甲基吡唑啉之后，通过取代的酰基hydr与三氟甲基1,3-二羰基芳烃之间的热缩合反应，制备了一系列类似物。结构-活性关系（SAR）研究表明，RHS的2和3位以及LHS末端苯环的2、3和4位上的小亲脂性取代基提高了活性，从而产生了一类新的强效和选择性的SOCE抑制剂。
• Inhibitors of HCV NS5B polymerase
  申请人：Yang Fan

  公开号：US20050154056A1

  公开（公告）日：2005-07-14

  The present invention relates to compounds, process for their synthesis, compositions and methods for the treatment and prevention of hepatitis C virus (HCV) infection. In particular, the present invention provides novel compounds, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment or prevention of HCV infection. The present invention also provides processes and intermediates for the synthesis of these compounds.

  本发明涉及化合物、其合成方法、组合物以及用于治疗和预防丙型肝炎病毒（HCV）感染的方法。具体而言，本发明提供了新颖的化合物，含有这些化合物的药物组合物以及使用这些化合物治疗或预防HCV感染的方法。本发明还提供了用于合成这些化合物的方法和中间体。
• Synthesis and structure–activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: high affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment
  作者：William L. Neumann、Karin E. Sandoval、Shirin Mobayen、Mahsa Minaeian、Stephen G. Kukielski、Khush N. Srabony、Rafael Frare、Olivia Slater、Susan A. Farr、Michael L. Niehoff、Audrey Hospital、Maria Kontoyianni、A. Michael Crider、Ken A. Witt

  DOI：10.1039/d1md00044f

  日期：——

  Somatostatin receptor-4 (SST4) is highly expressed in brain regions affiliated with learning and memory. SST4 agonist treatment may act to mitigate Alzheimer's disease (AD) pathology. An integrated approach to SST4 agonist lead optimization is presented herein. High affinity and selective agonists with biological efficacy were identified through iterative cycles of a structure-based design strategy

  生长抑素受体 4 (SST 4 ) 在与学习和记忆相关的大脑区域中高度表达。SST 4激动剂治疗可起到减轻阿尔茨海默病 (AD) 病理学的作用。本文介绍了 SST 4激动剂先导优化的综合方法。通过包含计算方法、化学和临床前药理学的基于结构的设计策略的迭代循环，确定了具有生物功效的高亲和力和选择性激动剂。我们先前报道的命中 ( 4 )的 1,2,4-三唑衍生物显示出增强的 SST 4结合亲和力、活性和选择性。35 种化合物显示出低纳摩尔范围的 SST 4结合亲和力，12 种具有K i < 1 nM。与 SST 2A相比，这些化合物对 SST 4的亲和力 > 500 倍。SST 4活性与各自的 SST 4结合亲和力一致（34 种化合物的 EC 50 < 10 nM）。化合物208（SST 4 K i = 0.7 nM；EC 50 = 2.5 nM；比 SST 2A高 600 倍以上的选择性）显
• Structure Activity Relationship of Brevenal Hydrazide Derivatives
  作者：Allan Goodman、Jennifer McCall、Henry Jacocks、Alysha Thompson、Daniel Baden、William Abraham、Andrea Bourdelais

  DOI：10.3390/md12041839

  日期：——

  Brevenal is a ladder frame polyether produced by the dinoflagellate Karenia brevis. This organism is also responsible for the production of the neurotoxic compounds known as brevetoxins. Ingestion or inhalation of the brevetoxins leads to adverse effects such as gastrointestinal maladies and bronchoconstriction. Brevenal shows antagonistic behavior to the brevetoxins and shows beneficial attributes when administered alone. For example, in an asthmatic sheep model, brevenal has been shown to increase tracheal mucosal velocity, an attribute which has led to its development as a potential treatment for Cystic Fibrosis. The mechanism of action of brevenal is poorly understood and the exact binding site has not been elucidated. In an attempt to further understand the mechanism of action of brevenal and potentially develop a second generation drug candidate, a series of brevenal derivatives were prepared through modification of the aldehyde moiety. These derivatives include aliphatic, aromatic and heteroaromatic hydrazide derivatives. The brevenal derivatives were tested using in vitro synaptosome binding assays to determine the ability of the compounds to displace brevetoxin and brevenal from their native receptors. A sheep inhalation model was used to determine if instillation of the brevenal derivatives resulted in bronchoconstriction. Only small modifications were tolerated, with larger moieties leading to loss of affinity for the brevenal receptor and bronchoconstriction in the sheep model.

  Brevenal是一种由 dinoflagellate Karenia brevis 产生的梯级框架聚醚。这种生物体也负责生成被称为 brevetoxins 的神经毒素化合物。摄入或吸入这些神经毒素会导致不良反应，如胃肠疾病和支气管收缩。Brevenal 对 brevetoxins 显示出拮抗作用，并且在单独使用时显示出有益特性。例如，在哮喘羊模型中，Brevenal 显示出能够增加气管黏膜速度，这一特性促使其被开发为潜在的囊性纤维化治疗药物。Brevenal 的作用机制尚不清楚，具体的结合位点尚未阐明。为进一步理解 brevenal 的作用机制并可能开发第二代药物候选物，通过对醛基部分进行修改，合成了一系列 brevenal 衍生物。这些衍生物包括脂肪族、芳香族和杂芳香族肼衍生物。使用体外突触体结合实验测试了这些 brevenal 衍生物，以确定它们对原生受体的 brevetoxin 和 brevenal 的置换能力。采用羊的吸入模型来确定 brevenal 衍生物的滴入是否导致支气管收缩。仅允许小幅度修改，较大的官能团则导致对 brevenal 受体的亲和力下降，并在羊模型中导致支气管收缩。
• Synthesis, urease inhibition, antioxidant and antibacterial studies of some 4-amino-5-aryl-3H-1,2,4-triazole-3-thiones and their 3,6-disubstituted 1,2,4-triazolo[3,4-b]1,3,4-thiadiazole derivatives
  作者：Muhammad Hanif、Muhammad Saleem、Muhammad Tahir Hussain、Nasim Hasan Rama、Sumera Zaib、Muhammad Adil M. Aslam、Peter G. Jones、Jamshed Iqbal

  DOI：10.1590/s0103-50532012000500010

  日期：——

  salts in dilute aqueous solution of hydrazine hydrate. These salts were formed by the reaction of acid hydrazides and carbon disulfide in methanolic potassium hydroxide solution at 0-5 °C. 4-Amino-5-aryl-3H-1,2,4-triazole-3-thiones were condensed with different substituted aromatic acids to yield 3,6-disubstituted-1,2,4-triazolo[3,4-b]1,3,4-thiadiazoles. The structures of the synthesized compounds were

  通过将肼基碳二硫代钾盐在水合肼的稀水溶液中回流，合成了一系列新的带有各种甲氧基苄基和甲氧基苯乙基的4-氨基-5-芳基-3H-1,2,4-三唑-3-硫酮。这些盐是通过酰肼与二硫化碳在甲醇氢氧化钾溶液中于0-5°C反应形成的。将4-氨基-5-芳基-3H-1,2,4-三唑-3-硫酮与不同的取代芳族酸缩合，生成3,6-二取代-1,2,4-三唑[3,4-b] 1,3,4-噻二唑。合成的化合物的结构通过红外（IR），1H和13C核磁共振（NMR），元素分析和质谱（MS）研究进行了表征。筛选所有合成的化合物的脲酶抑制作用，抗氧化剂和抗菌活性。一些化合物显示出优异的脲酶抑制活性，超过了标准药物。其他人表现出强大的抗氧化活性。与标准药物相比，所有化合物均显示出显着的抗菌活性。